

Olmecar™

Olmesartan Medoxomil EP

COMPOSITION

Olmecar™ 10 Tablet: Each tablet contains Olmesartan Medoxomil EP 10 mg.

Olmecar™ 20 Tablet: Each tablet contains Olmesartan Medoxomil EP 20 mg.

Olmecar™ 40 Tablet: Each tablet contains Olmesartan Medoxomil EP 40 mg.

PHARMACOLOGY

Olmesartan Medoxomil is a selective angiotensin II receptor antagonist (AT1 subtype). Olmesartan Medoxomil a prodrug, is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract.

INDICATION

Hypertension.

DO dosage & ADMINISTRATION

The starting dose is 10 mg once daily and maximum dose is 40 mg once daily. In patients whose blood pressure is not adequately controlled at the starting dose, the dose of Olmesartan medoxomil may be increased to 20 mg once daily as the optimal dose.

USE IN PREGNANCY AND LACTATION

Pregnancy Categories: C (rst trimester) and D (second and third trimesters). Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

CONTRAINDICATION

Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.

SIDE EFFECTS

The following adverse events occurred in placebo-controlled clinical trials at an incidence of more than 1% of patients treated with Olmesartan, but also occurred at about the same or greater incidence in patients receiving placebo: back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, in uenza-like symptoms, pharyngitis, rhinitis, sinusitis etc.

PRECAUTION

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.

STORAGE CONDITION

Store in a cool and dry place below 30° C. Protect from light and moisture. Keep out of the reach of children.

HOW SUPPLIED

Olmecar™ 10 Tablet: Each box contains 30 tablets in blister pack.

Olmecar™ 20 Tablet: Each box contains 30 tablets in blister pack.

Olmecar™ 40 Tablet: Each box contains 30 tablets in blister pack.

Manufactured by



SQUARE
PHARMACEUTICALS LTD.
BANGLADESH